Trevena is a US-based clinical stage biopharmaceutical company. It discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors (GPCRs).
The company operates its business through single segment, biopharmaceutical products.
Trevena's clinical stage programs include TRV027 for the treatment of acute heart failure (AHF); TRV130 for the treatment of moderate to severe acute pain; TRV250, for the treatment-refractory migraine; and TRV734, oral agent for the treatment of moderate to severe acute and chronic pain. The company's additional program includes delta-opioid receptor G protein biased ligand therapeutics.
TRV027 is an intravenous drug for the treatment of AHF in combination with diuretic therapy and is currently being investigating in a Phase 2 clinical trial. TRV027 is a novel intravenous beta-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). In phase II A clinical trial, TRV027 rapidly reduced blood pressure and preserved renal, or kidney, function while preserving cardiac performance in advanced chronic heart failure patients.
TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate to severe acute pain, where intravenous therapy is preferred with a clinical development focus in acute postoperative pain. TRV130 activates the mu opioid G protein receptor pathway, in a manner similar to strong opioids such as morphine and fentanyl and like other drugs TRV130 is an analgesic in rodents. TRV130 is used for the treatment of moderate to severe acute pain intravenously.
TRV734 is a small molecule G protein biased ligand targeting the m-opioid receptor. TRV734 is used for the treatment of moderate to severe acute and chronic pain orally.
TRV250 is an Oral Delta Opioid biased ligand for treatment of refractory migraine, which is in the preclinical development stage. The company focuses on the discovery of a novel, orally bioavailable and small molecule delta opioid (d-opioid) receptor G protein biased ligand used for the treatment of central nervous system (CNS) disorders such as Parkinson's disease, pain or depression.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Trevena, Inc. in terms of revenue, net income, and operating income.
-- Financials - Details about Trevena, Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Trevena, Inc.’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Trevena, Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Trevena, Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Trevena, Inc. operate and what are key points about it?
-- What is the product / service portfolio of Trevena, Inc.?
-- How has Trevena, Inc. performed financially from the 2013?
-- How does Trevena, Inc. rank among its peers in terms of revenue and market share?
-- What are Trevena, Inc. strengths and weaknesses and what opportunities and threats does it face?
-- What are Trevena, Inc.’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Trevena, Inc.? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years